Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

Author's Avatar
Feb 16, 2021
Article's Main Image

Resulting patent to extend Viracta's intellectual property protection into at least 2040

PR Newswire